Edwards Lifesciences holder plans 818,958-share sale

Edwards Lifesciences Corporation is the issuer for a planned resale of its common stock disclosed by shareholder Wayne Markowitz.

Rhea-AI Filing Summary

Edwards Lifesciences Corporation is the issuer for a planned resale of its common stock disclosed by shareholder Wayne Markowitz. The notice covers up to 818,958 shares of common stock to be sold through broker Charles Schwab & Co., Inc., with the stock listed on the NYSE. The company reports 575,800,000 shares outstanding of this class as of the notice. The planned transaction is associated with an employee stock option exercise and a broker payment for a cashless exercise. During the prior three months, a separate sale of 593 shares occurred on May 11, 2026 for total proceeds of $47,280.

Key Figures

Planned shares to be sold: 818,958 shares Shares outstanding: 575,800,000 shares Prior shares sold: 593 shares +2 more

5 metrics

Planned shares to be sold 818,958 shares Common stock to be sold through Charles Schwab & Co., Inc.

Shares outstanding 575,800,000 shares Outstanding common shares of the same class referenced in the notice

Prior shares sold 593 shares Sale during the past three months on 05/11/2026

Prior sale proceeds $47,280 Aggregate proceeds from 593-share sale on 05/11/2026

Planned sale date 07/28/2026 Approximate date of sale for the 818,958 shares

Key Terms

Form 144, Employee Stock Option Exercise, cashless exercise, aggregate market value

4 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Employee Stock Option Exercise financial

"Common | 07/28/2026 | Employee Stock Option Exercise"

cashless exercise financial

"Broker Payment for Cashless Exercise"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

aggregate market value financial

"144: Securities Information ... aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock sale is disclosed for Edwards Lifesciences (EW) in this Form 144?

The notice discloses a planned sale of up to 818,958 shares of Edwards Lifesciences common stock through broker Charles Schwab & Co., Inc., with the shares listed for trading on the NYSE.

Who is the reporting shareholder in the Edwards Lifesciences (EW) Form 144?

The reporting security holder is Wayne Markowitz, associated with Edwards Lifesciences Corporation at One Edwards Way, Irvine, California, as shown in the Form 144 notice of proposed sale.

How many Edwards Lifesciences (EW) shares are outstanding in the Form 144 notice?

The notice states that 575,800,000 shares of Edwards Lifesciences common stock are outstanding. This figure serves as a baseline for comparing the planned resale amount to the total shares of that class.

What prior sales of Edwards Lifesciences (EW) stock are listed in the Form 144?

Over the prior three months, the notice lists a sale on May 11, 2026 of 593 shares of Edwards Lifesciences common stock, for aggregate proceeds of $47,280 from that transaction.

How is the Edwards Lifesciences (EW) stock sale related to employee options?

The Form 144 describes the planned transaction as tied to an Employee Stock Option Exercise with a broker payment for a cashless exercise, indicating the sale is associated with exercising stock options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/28/2026 - 04:19 PM Accepted by SEC EDGAR 07/28/2026 - 04:18 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001991414
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Edwards Lifesciences Corp
SEC File Number	001-15525
Address of Issuer	ONE EDWARDS WAY IRVINE CALIFORNIA 92614
Phone	9492502500
Name of Person for Whose Account the Securities are To Be Sold	Markowitz Wayne
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	9628	818958.00	575800000	07/28/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/28/2026	Employee Stock Option Exercise	EDWARDS LIFESCIENCES CORPORATION			9628	07/28/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
WAYNE MARKOWITZ ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	05/11/2026	593	47280.00

144: Remarks and Signature

Remarks
Date of Notice	07/28/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	WAYNE MARKOWITZ
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)